江汉大学学报（自然科学版）2024，Vol.52Issue(2)：28-33,6.DOI:10.16389/j.cnki.cn42-1737/n.2024.02.004
达拉非尼联合曲美替尼治疗ALK与BRAF基因双突变晚期肺腺癌1例
A Case of Advanced Lung Adenocarcinoma with ALK and BRAF Mutations Treated with Dabrafenib Plus Trametinib
伍越 1张思佳 2镇鸿燕 1龙志雄3
作者信息
- 1. 江汉大学 医学部,湖北 武汉 430056
- 2. 华中科技大学 同济医学院附属协和医院肿瘤中心,湖北 武汉 430021
- 3. 武汉市第五医院 肿瘤科,湖北 武汉 430050
- 折叠
摘要
Abstract
Objective Coexisting ALK and BRAF mutations are extremely rare in non-small cell lung cancer(NSCLC),and effective treatment options are not yet supported by clinical cases and data,thus this report is expected to provide a clinical reference for treating this group of patients.Methods To report a case of advanced lung adenocarcinoma in an 86-year-old female with coexisting ALK fusion and BRAF mutation,who was treated with dabrafenib plus trametinib.Results In our case,the patient achieved partial response(PR)after the treatment,and no serious adverse reactions were observed during the treatment.Conclusion With the rapid development of gene detection technology and bio-targeted drugs,the survival rate and life quality of patients with advanced NSCLC have been improved.This patient showed definite efficacy for dabrafenib plus trametinib,which provides a significant reference to the clinical diagnosis and treatment of NSCLC with ALK and BRAF mutations.关键词
非小细胞肺癌/ALK融合/BRAF突变/靶向治疗/病例报告Key words
non-small cell lung cancer(NSCLC)/ALK fusion/BRAF mutation/targeted therapy/case reports分类
医药卫生引用本文复制引用
伍越,张思佳,镇鸿燕,龙志雄..达拉非尼联合曲美替尼治疗ALK与BRAF基因双突变晚期肺腺癌1例[J].江汉大学学报（自然科学版）,2024,52(2):28-33,6.
